LY6K is a Novel Molecular Target in Bladder Cancer on Basis of Integrate Genome-wide Profiling

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 Nov 11

PMID 21063397

Citations 33

Authors

R Matsuda

H Enokida

T Chiyomaru

N Kikkawa

T Sugimoto

K Kawakami

S Tatarano

H Yoshino

K Toki

Y Uchida

K Kawahara

K Nishiyama

N Seki

M Nakagawa

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study is to find a novel molecular target based on chromosomal alteration and array-based gene expression analyses in bladder cancer (BC). We investigated a cancer testis antigen, LY6K, which is located on chromosome 8q24.3.

Methods: Five BC cell lines were subjected to high-resolution array-comparative genomic hybridisation with 244 000 probes. The expression levels of LY6K mRNA were evaluated in BC cell lines and clinical BC specimens by real-time reverse transcription-PCR. The cell lines were subjected to fluorescence in situ hybridisation of LY6K. Cell viability was evaluated by cell growth, wound healing, and matrigel invasion assays.

Results: Typical gained loci (P<0.0001) at 6p21.33-p21.32, 8q24.3, 9q34.13, 11q13.1-q14.1, 12q13.12-q13.13, 16p13.3, and 20q11.21-q13.33 were observed in all of the cell lines. We focused on 8q24.3 locus where LY6K gene harbours, and it was the top upregulated one in the gene profile from the BC cell line. LY6K mRNA expression was significantly higher in 91 BCs than in 37 normal bladder epitheliums (P<0.0001). Fluorescence in situ hybridisation validated that the high LY6K mRNA expression was due to gene amplification in the region where the gene harbours. Cell viability assays demonstrated that significant inhibitions of cell growth, migration, and invasion occured in LY6K knock down BC cell lines; converse phenomena were observed in a stable LY6K transfectant; and LY6K knockdown of the transfectant retrieved the original phenotype from the LY6K transfectant.

Conclusion: Upregulation of the oncogenic LY6K gene located on the gained locus at 8q24.3 may contribute BC development.

Citing Articles

A Phase 2 Study of S-588410 Maintenance Monotherapy for Platinum-Treated Advanced or Metastatic Urothelial Carcinoma.

Shimizu N, Hussain S, Obara W, Yamasaki T, Takashima S, Hasegawa T Bladder Cancer. 2024; 8(2):179-192.

PMID: 38993370 PMC: 11181746. DOI: 10.3233/BLC-211592.

Silencing LY6D Expression Inhibits Colon Cancer in Xenograft Mice and Regulates Colon Cancer Stem Cells' Proliferation, Stemness, Invasion, and Apoptosis via the MAPK Pathway.

Duan J, Wang Y, Chen Y, Wang Y, Li Q, Liu J Molecules. 2023; 28(23).

PMID: 38067506 PMC: 10708431. DOI: 10.3390/molecules28237776.

Genome instability-derived genes as a novel prognostic signature for lung adenocarcinoma.

Zhang X, Lam T, Ting H Front Cell Dev Biol. 2023; 11:1224069.

PMID: 37655157 PMC: 10467266. DOI: 10.3389/fcell.2023.1224069.

Lymphocyte antigen 6K signaling to aurora kinase promotes advancement of the cell cycle and the growth of cancer cells, which is inhibited by LY6K-NSC243928 interaction.

Chellakkan Selvanesan B, Varghese S, Andrys-Olek J, Arriaza R, Prakash R, Tiwari P Cancer Lett. 2023; 558:216094.

PMID: 36805500 PMC: 10044439. DOI: 10.1016/j.canlet.2023.216094.

Establishing a Novel Gene Signature Related to Histone Modifications for Predicting Prognosis in Lung Adenocarcinoma.

Liu M, Yu X, Xu S, Qu C J Oncol. 2022; 2022:8802573.

PMID: 36193203 PMC: 9525801. DOI: 10.1155/2022/8802573.

References

Shinoda Y, Kozaki K, Imoto I, Obara W, Tsuda H, Mizutani Y . Association of KLK5 overexpression with invasiveness of urinary bladder carcinoma cells. Cancer Sci. 2007; 98(7):1078-86. PMC: 11158320. DOI: 10.1111/j.1349-7006.2007.00495.x. View

Dyrskjot L, Thykjaer T, Kruhoffer M, Jensen J, Marcussen N, Hamilton-Dutoit S . Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2002; 33(1):90-6. DOI: 10.1038/ng1061. View

Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K . Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009; 100(8):1502-9. PMC: 11158753. DOI: 10.1111/j.1349-7006.2009.01200.x. View

Pollack J, Sorlie T, Perou C, Rees C, Jeffrey S, Lonning P . Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A. 2002; 99(20):12963-8. PMC: 130569. DOI: 10.1073/pnas.162471999. View

Imao T, Koshida K, Endo Y, Uchibayashi T, Sasaki T, Namiki M . Dominant role of E-cadherin in the progression of bladder cancer. J Urol. 1999; 161(2):692-8. View

Inazawa J, Inoue J, Imoto I . Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancer-related genes. Cancer Sci. 2004; 95(7):559-63. PMC: 11158872. DOI: 10.1111/j.1349-7006.2004.tb02486.x. View

Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg R, Klopocki E . Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest. 2004; 84(4):465-78. DOI: 10.1038/labinvest.3700068. View

Scanlan M, Simpson A, Old L . The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004; 4:1. View

Lee J, Lee Y, Yoo K, Lee K, Park K, Ahn T . LY-6K gene: a novel molecular marker for human breast cancer. Oncol Rep. 2006; 16(6):1211-4. View

10.

Reichling T, Goss K, Carson D, Holdcraft R, Ley-Ebert C, Witte D . Transcriptional profiles of intestinal tumors in Apc(Min) mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors. Cancer Res. 2005; 65(1):166-76. View

11.

Hovey R, Chu L, Balazs M, DeVries S, Moore D, Sauter G . Genetic alterations in primary bladder cancers and their metastases. Cancer Res. 1998; 58(16):3555-60. View

12.

Zaharieva B, Simon R, Diener P, Ackermann D, Maurer R, Alund G . High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol. 2003; 201(4):603-8. DOI: 10.1002/path.1481. View

13.

von Knobloch R, Bugert P, Jauch A, Kalble T, Kovacs G . Allelic changes at multiple regions of chromosome 5 are associated with progression of urinary bladder cancer. J Pathol. 2000; 190(2):163-8. DOI: 10.1002/(SICI)1096-9896(200002)190:2<163::AID-PATH509>3.0.CO;2-0. View

14.

Choi S, Kong H, Park S, Park J . Metastatic effect of LY-6K gene in breast cancer cells. Int J Oncol. 2009; 35(3):601-7. DOI: 10.3892/ijo_00000371. View

15.

Simon R, Burger H, Semjonow A, Hertle L, Terpe H, Bocker W . Patterns of chromosomal imbalances in muscle invasive bladder cancer. Int J Oncol. 2000; 17(5):1025-9. DOI: 10.3892/ijo.17.5.1025. View

16.

Zhao J, Richter J, Wagner U, Roth B, Schraml P, Zellweger T . Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res. 1999; 59(18):4658-61. View

17.

Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H . Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 2007; 67(24):11601-11. DOI: 10.1158/0008-5472.CAN-07-3243. View

18.

Kawakami K, Enokida H, Tachiwada T, Gotanda T, Tsuneyoshi K, Kubo H . Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling. Oncol Rep. 2006; 16(3):521-31. View

19.

Qiu D, Katanoda K, Marugame T, Sobue T . A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer. 2008; 124(2):443-8. DOI: 10.1002/ijc.23911. View

20.

Mahdy E, Pan Y, Wang N, Malmstrom P, Ekman P, Bergerheim U . Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade. Anticancer Res. 2002; 21(5):3167-73. View